NOF (4403) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
6 Aug, 2025Executive summary
Net sales for the first quarter rose 1.7% year-over-year to ¥56,063 million, but operating profit fell 12.5% and profit attributable to owners of parent dropped 22.1% year-over-year.
The business environment was impacted by global economic uncertainty, high raw material and fuel prices, and policy risks, though Japan showed some economic recovery.
The company continued to pursue its mid-term management plan, focusing on market expansion, new product development, productivity, safety, and CSR.
Financial highlights
Operating profit for the quarter was ¥11,847 million, down from ¥13,533 million year-over-year.
Ordinary profit decreased 19.0% year-over-year to ¥12,274 million.
Profit attributable to owners of parent was ¥8,610 million, a 22.1% decrease year-over-year.
Basic earnings per share for the quarter was ¥37.00, down from ¥46.30 year-over-year.
Comprehensive income for the quarter was ¥11,368 million, down 7.9% year-over-year.
Outlook and guidance
Full-year consolidated earnings forecast remains unchanged: net sales ¥252,000 million (+5.7%), operating profit ¥46,000 million (+1.5%), profit attributable to owners of parent ¥36,800 million (+0.8%).
Annual dividend forecast is ¥48.00 per share, up from ¥45.00 in the previous year.
Latest events from NOF
- Net sales up, profits down; strong explosives growth; dividend and share buyback increased.4403
Q3 202613 Feb 2026 - Profits fell but full-year outlook and shareholder returns were raised on segment growth.4403
Q2 202618 Nov 2025 - Sales and profits climbed in H1 FY2024, with guidance and shareholder returns both increased.4403
Q2 202513 Jun 2025 - Strong Q1 profit growth driven by Functional Chemicals; full-year outlook maintained.4403
Q1 202513 Jun 2025 - Record profits, higher dividends, and robust capital returns drive future growth.4403
Q4 20256 Jun 2025 - Sales and profits rose, driven by Functional Chemicals, with stable outlook and shareholder returns.4403
Q3 20255 Jun 2025